Portfolio

Portfolio

Ligand has assembled one of the largest and most diverse portfolios in the biotech and pharmaceutical industry. Our partners and licensees fund the development and commercialization of our portfolio and we are entitled to receive royalties and milestones on program success. Currently approved portfolio drugs include those that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Our partners and licensees have programs currently in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. 

View Portfolio

The Big 6

Ligand has identified six drugs from the portfolio that stand out due to potential market size of indication, upcoming milestone events and/or potentially significant deal economics.

Program

Baxdela (delafloxacin)

Therapeutic Area

Infection

Stage Royalty Rate
NDA 2.5%

Program

Sparsentan

Therapeutic Area

FSGS - Kidney Disease

Stage Royalty Rate
Phase II/III 9%

Program

Brexanolone (SAGE-547)

Therapeutic Area

Neurology

Stage Royalty Rate
Phase III 3%

Program

Lasofoxifene

Therapeutic Area

Cancer/Women's Health

Stage Royalty Rate
Phase II/III 6.0-10.0%

Program

BMS986231

Therapeutic Area

Cardiovascular

Stage Royalty Rate
Phase II/III 2.0-3.0%

Program

Prexasertib

Therapeutic Area

Cancer

Stage Royalty Rate
Phase II 1.5-3.0%

Portfolio

Ligand has assembled one of the largest portfolios of assets among our peers that covers a diverse array of indications.

Partners and Licensees

Ligand has established alliances with the world's leading pharmaceutical companies.